-
Mashup Score: 31No more 'ick' factor? A colon cancer blood test may be coming. - 13 day(s) ago
The blood test, which is up for FDA approval this year, would not replace colonoscopy, experts said.
Source: www.nbcnews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 30No more 'ick' factor? A colon cancer blood test may be coming. - 15 day(s) ago
The blood test, which is up for FDA approval this year, would not replace colonoscopy, experts said.
Source: www.nbcnews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 30No more 'ick' factor? A colon cancer blood test may be coming. - 16 day(s) ago
The blood test, which is up for FDA approval this year, would not replace colonoscopy, experts said.
Source: www.nbcnews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
ESMO Deep Dive: Lower Digestive Cancers – Insights from Biology and Clinical Research in the Management of Patients with Molecularly-Defined Subgroups of Metastatic Colorectal CancersChair: Clara MontagutSpeakers: Andrea Sartore-Bianchi, Julien Taieb, Dominik Paul Modest, Elena Élez(Reserved to ESMO Members)
Source: oncologypro.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The 'ESMO Deep Dive: Lower Digestive Cancers - Insights from biology & clinical research in the managemt of pts w/ molecularly-defined subgroups of metastatic #colorectalcancers' now available on OncologyPRO https://t.co/CNl6DX1sz0 #CRCSM @ClaraMontagut @ModestDominik @elena_elez https://t.co/oBHGlaNP3o
-
-
Mashup Score: 1ESMO Deep Dive: Lower Digestive Cancers - Insights from Biology - 11 month(s) ago
This ESMO Webinar Series is available to all ESMO Members.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join us for the 'ESMO Deep Dive: Lower Digestive Cancers - Insights from biology & clinical research in the managemt of pts w/ molecularly-defined subgroups of metastatic #colorectalcancers' 10/5, 18:30 CEST https://t.co/dhskRVHMEK #CRCSM @ClaraMontagut @ModestDominik @elena_elez https://t.co/BkjnPfCMK7
-
-
Mashup Score: 0RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status - Oncogene - 12 month(s) ago
More than 30% of all human cancers are driven by RAS mutations and activating KRAS mutations are present in 40% of colorectal cancer (CRC) in the two main CRC subgroups, MSS (Microsatellite Stable) and MSI (Microsatellite Instable). Studies in RAS-driven tumors have shown essential roles of the RAS effectors RAF and specifically of RAF1, which can be dependent or independent of RAF’s ability to…
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
This cohort study examines all-cause and cancer-specific mortality among patients in the Veterans Affairs health system whose colorectal cancer was not detected by colonoscopy.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1ESMO Deep Dive: Lower Digestive Cancers - Oligometastatic - 12 month(s) ago
This ESMO Webinar Series is available to all ESMO Members.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Airing today (5/4): take your knowledge on oligometastatic #colorectalcancers to the next level & get your questions answered by leading specialists. Access with your ESMO Member account: https://t.co/0I0PZwSvS2 #CRCSM @DucreuxMichel @DrClaireGallois @BaereThierry @tgruenberger https://t.co/pnpegRdgay
-
-
Mashup Score: 5ESMO Deep Dive: Lower Digestive Cancers - Oligometastatic - 1 year(s) ago
This ESMO Webinar Series is available to all ESMO Members.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gain a deeper understanding of current & future tx for oligometastatic #colorectalcancers. Join this live discussion w/ experts & get yr questions answered. Access w/ yr ESMO membership: https://t.co/JTkCNEKWp0 #CRCSM @DucreuxMichel @DrClaireGallois @BaereThierry @tgruenberger https://t.co/1v7JbwHvuH
-
-
Mashup Score: 3
It remains critical to identify colorectal cancers (CRC) that will disseminate as early as possible. Here, the authors identify CRC tumours that are aggressive and prone to early dissemination, characterised by epithelial TGFβ and growth-factor signalling – which could be targeted with MEK/EGFR inhibitors.
Source: NatureCategories: General Medicine News, Latest HeadlinesTweet
New research published in @NEJM led by Dr. William Grady and co-authored by @IssakaMD of Fred Hutch found that a blood test called Shield from California-based Guardant Health was, overall, 83% effective in finding #colorectalcancers. https://t.co/qH02udNoq0